|
CO-ADMINISTRATION HAS RESULTED IN ELEVATED CARBAMAZEPINE LEVELS
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
ANTIDIURETIC EFFECT IS POTENTIATED BY THE DRUG
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
MAY POTENTIALLY INCREASE THE RISK FOR ACETAMINOPHEN INDUCED HEPATOTOXICITY
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED SERUM LEVELS OF CARBAMAZEPINE RESULTING IN TOXICITY IN SOME PATIENTS
|
ANTAGONISE ANTIEPILEPTIC EFFECTS OF THE DRUG
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|